Cosmos Health Purchases an Additional $500,000 in Ethereum Pursuant to its $300 Million Digital Assets Facility

Rhea-AI Summary

Cosmos Health (NASDAQ:COSM) announced on October 10, 2025 that it purchased an additional $500,000 of Ethereum (ETH), bringing its total ETH holdings to $1.5 million. The purchase was executed under the company’s existing $300 million digital assets facility as part of a balance-sheet diversification strategy and to explore blockchain-enabled healthcare solutions. Management reiterated intent to continue using the financing facility and described digital assets as both long-term investments and potential enablers of decentralized healthcare applications.

CHICAGO, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. ("Cosmos Health" or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global healthcare group, today announced that it has purchased an additional $500,000 worth of Ethereum (ETH), bringing its total investment in ETH to $1.5 million.

This acquisition was executed pursuant to Cosmos Health’s previously announced $300 million digital assets facility, which is part of the Company’s broader strategic initiative to diversify its balance sheet and leverage blockchain technology within the healthcare and digital wellness sectors.

Greg Siokas, CEO of Cosmos Health, stated: “We are pleased to continue our Ethereum purchases and reiterate our commitment to fully leveraging our $300 million financing facility. We are already seeing gains from our earlier Ethereum investments, and with increased usage and adoption, we believe there is potential for further appreciation. We view select digital assets such as Ethereum not only as long-term investments, but also as potential enablers of secure, decentralized healthcare solutions.”

About Cosmos Health Inc.

Cosmos Health Inc. (Nasdaq:COSM), incorporated in 2009 in Nevada, is a diversified, vertically integrated global healthcare group. The Company owns a portfolio of proprietary pharmaceutical and nutraceutical brands, including Sky Premium Life®, Mediterranation®, bio-bebe®, C-Sept® and C-Scrub®. Through its subsidiary Cana Laboratories S.A., licensed under European Good Manufacturing Practices (GMP) and certified by the European Medicines Agency (EMA), it manufactures pharmaceuticals, food supplements, cosmetics, biocides, and medical devices within the European Union. Cosmos Health also distributes a broad line of pharmaceuticals and parapharmaceuticals, including branded generics and OTC medications, to retail pharmacies and wholesale distributors through its subsidiaries in Greece and the UK. Furthermore, the Company has established R&D partnerships targeting major health disorders such as obesity, diabetes, and cancer, enhanced by artificial intelligence drug repurposing technologies, and focuses on the R&D of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products. Cosmos Health has also entered the telehealth space through the acquisition of ZipDoctor, Inc., based in Texas, USA. With a global distribution platform, the Company is currently expanding throughout Europe, Asia, and North America, and has offices and distribution centers in Thessaloniki and Athens, Greece, and in Harlow, UK. More information is available at www.cosmoshealthinc.com, www.skypremiumlife.com, www.cana.gr, www.zipdoctor.co, www.cloudscreen.gr, as well as LinkedIn and X.

Forward-Looking Statements
With the exception of the historical information contained in this news release, the matters described herein may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Words such as “believes,” “expects,” “anticipates,” “intends,” “projects,” “estimates,” “plans,” and similar expressions, or future or conditional verbs such as “will,” “should,” “would,” “may,” and “could,” generally identify forward-looking statements, although not all forward-looking statements contain these words. These statements involve risks and uncertainties that may individually or materially affect the matters discussed herein for a variety of reasons outside the Company’s control, including, but not limited to: the Company’s ability to raise sufficient financing to implement its business plan; the effectiveness of its digital asset strategies, including accumulation and yield-generating activities; the impact of the war in Ukraine on the Company’s business, operations, and the economy in general; and the Company’s ability to successfully develop and commercialize its proprietary products and technologies. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results could differ materially from those anticipated. Readers are encouraged to review the risk factors set forth in the Company’s filings with the SEC, which are available at the SEC’s website (www.sec.gov). The Company disclaims any obligation to update or revise forward-looking statements, whether as a result of new information, future events, or otherwise

Investor Relations Contact:
BDG Communications
cosm@bdgcommunications.com

FAQ

How much Ethereum did Cosmos Health (COSM) buy on October 10, 2025?

Cosmos Health purchased an additional $500,000 of Ethereum on October 10, 2025, bringing total ETH holdings to $1.5 million.

Under what authority did COSM execute the $500,000 Ethereum purchase?

The purchase was executed pursuant to Cosmos Health’s existing $300 million digital assets facility.

What is Cosmos Health’s stated purpose for holding Ethereum (COSM)?

The company says it is diversifying its balance sheet and exploring Ethereum as a long-term investment and an enabler of decentralized healthcare solutions.

Does the October 2025 Ethereum purchase materially change COSM’s balance sheet?

The company reports total ETH holdings of $1.5 million, which is a disclosure item but not presented as a material change to the balance sheet.

Will Cosmos Health continue to use the $300 million digital assets facility (COSM)?

Management reiterated its commitment to fully leveraging the $300 million financing facility, indicating intent to continue purchases under the facility.